Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

被引：1

作者：

Murakami, H. ^{[1
]}

Yamamoto, N. ^{[1
,3
]}

Boku, N. ^{[2
]}

Yamazaki, K. ^{[2
]}

Yamamoto, N. ^{[1
,3
]}

Yamada, Y. ^{[4
]}

Yamada, K. ^{[3
]}

Puchalski, T. ^{[5
]}

Shin, E. ^{[6
]}

Tamura, T. ^{[3
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka 104, Japan

[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol & Endoscopy, Shizuoka 104, Japan

[3] Natl Canc Ctr, Div Internal Med, Tokyo, Japan

[4] Natl Canc Ctr, Div Gastrointestinal Oncol, Tokyo, Japan

[5] AstraZeneca, Res & Dev, Wilmington, DE USA

[6] AstraZeneca, Res & Dev, Osaka, Japan

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 12期

关键词：

D O I：

10.1016/S1359-6349(08)72328-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：124 / 124

页数：1

共 50 条

[21] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
Xu, J.
Wang, Y.
Ye, C. Y.
Huang, C.
Zhang, X. H.
Sai, Y.
Shen, L.
Mu, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[22] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
Song, Zhengbo
Hui, Ai-min
Wu, Zhuli
Liu, Huilong
Cheng, Xiangdong
CANCER RESEARCH, 2022, 82 (12)
[23] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors
Xu, Jian-Ming
Wang, Yan
Shen, Lin
Gong, Jifang
Huang, Cheng
Ye, Chen Yang
Yang, Li
Sai, Yang
Mu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[24] Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results
Takahashi, S.
Shimizu, T.
Doi, T.
Lopez-Vilarino, J. A.
Nunez Martin, R.
Kahatt, C.
Fernandez Teruel, C.
Sasamoto, H.
Zeaiter, A.
ANNALS OF ONCOLOGY, 2020, 31 : S478 - S478
[25] PHASE I STUDY OF RESMINOSTAT, AN ORAL HDAC INHIBITOR, IN JAPANESE PATIENTS WITH SOLID TUMORS
Kitazono, Satoru
Fujiwara, Yutaka
Nakamichi, Shinji
Mizugaki, Hidenori
Nokihara, Hiroshi
Yamamoto, Noboru
Yamada, Yasuhide
Tamura, Tomohide
ANNALS OF ONCOLOGY, 2014, 25
[26] Docetaxel and ifosfamide in patients with advanced solid tumors: Results of a phase I study
Pronk, LC
Schrijvers, D
Schellens, JHM
de Bruijn, EA
Planting, AST
Locci-Tonelli, D
Groult, V
Verweij, J
van Oosterom, AT
SEMINARS IN ONCOLOGY, 1998, 25 (01) : 23 - 28
[27] Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors
Shimokata, T.
Watanabe, K.
Shibata, T.
Inada-Inoue, M.
Shirao, K.
Hirashima, Y.
Fukuhara, S.
Tokushige, K.
Zubel, A.
Ando, Y.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S870 - S871
[28] Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors
Seto, Takashi
Nosaki, Kaname
Shinoda, Gen
Hashizume, Kensei
Yamaguchi, Iku
Tsuburaya, Jun
Nogai, Hendrik
Shitara, Kohei
Yoh, Kiyotaka
ANNALS OF ONCOLOGY, 2016, 27
[29] A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
Wataru Okamoto
Takayuki Yoshino
Toshiaki Takahashi
Isamu Okamoto
Shinya Ueda
Asuka Tsuya
Narikazu Boku
Kazuto Nishio
Masahiro Fukuoka
Nobuyuki Yamamoto
Kazuhiko Nakagawa
Cancer Chemotherapy and Pharmacology, 2013, 72 : 1063 - 1071
[30] A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
Okamoto, Wataru
Yoshino, Takayuki
Takahashi, Toshiaki
Okamoto, Isamu
Ueda, Shinya
Tsuya, Asuka
Boku, Narikazu
Nishio, Kazuto
Fukuoka, Masahiro
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1063 - 1071

← 1 2 3 4 5 →